Jan 5 2011
BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel diagnostics, today announced the publication of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.
The study was conducted by the Department of Cardiology at the University Medical Centre Groningen in The Netherlands. The results of this prospective study, in which 592 HF patients were studied, confirm that galectin-3 is a strong and independent predictor of adverse outcomes. The prognostic value of galectin-3 remained even after adjustment for established risk factors for poor outcomes in HF, including age, sex, BNP, renal function, and diabetes mellitus.
Source BG Medicine
Linking lifestyle to longevity: How diet and hypertension sway risks for heart disease and cancer